(NYSE: HLN) Haleon's forecast annual revenue growth rate of 3.63% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Haleon's revenue in 2024 is $14,306,329,113.On average, 3 Wall Street analysts forecast HLN's revenue for 2024 to be $134,238,964,272,483, with the lowest HLN revenue forecast at $133,462,493,601,051, and the highest HLN revenue forecast at $134,715,255,886,964. On average, 3 Wall Street analysts forecast HLN's revenue for 2025 to be $140,211,886,626,374, with the lowest HLN revenue forecast at $139,325,616,872,091, and the highest HLN revenue forecast at $140,985,531,518,213.
In 2026, HLN is forecast to generate $147,174,081,171,058 in revenue, with the lowest revenue forecast at $146,741,072,004,122 and the highest revenue forecast at $147,945,168,085,946.